吡咯烷-1-羰酰亚胺盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 吡咯烷-1-羰酰亚胺盐酸盐
• 英文名称: pyrrolidine-1-carboximidamide hydroiodide
• 英文别名: Pyrrolidin-1-ium-1-ylidenemethanediamine;iodide；pyrrolidin-1-ium-1-ylidenemethanediamine;iodide
• 化学式: C₅H₁₁N₃*HI
• 分子量: 241.075
• InChiKey: XPASGQSDLPDWNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.59
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  53.1
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  吡咯烷-1-羰酰亚胺盐酸盐 、 sodium (Z)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 6-oxo-2-(pyrrolidin-1-yl)-1,6-dihydropyrimidine-4-carboxylic acid
  参考文献：
  名称：

  [EN] PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS
  [FR] COMPOSÉS DE PYRIMIDINONE AMIDE EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及嘧啶酮酰胺化合物，可能作为治疗中枢神经系统和/或与磷酸二酯酶2（PDE2）相关的外周障碍的治疗剂。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病、阿尔茨海默病、认知障碍、焦虑、抑郁症、偏头痛或亨廷顿病、帕金森病、帕金森病痴呆（PDD）和与纹状体功能不足或基底神经节功能障碍相关的其他疾病。

  公开号：

  WO2016186888A1

文献信息

• PHENYLTHIAZOLES AND USES THEREOF
  申请人：Purdue Research Foundation

  公开号：US20180319784A1

  公开（公告）日：2018-11-08

  Series of 2-phenyl-4-methylthiazole analogues are disclosed as potential therapeutic agents for the treatment of bacterial infections, especially methicillin-resistant Straphylococcus aureus (MRSA) related infections. A method for the treatment of MRSA-related infections is also claimed.

  一系列2-苯基-4-甲基噻唑类似物被披露为治疗细菌感染，特别是耐甲氧西林金黄色葡萄球菌（MRSA）相关感染的潜在治疗药物。还声明了一种治疗MRSA相关感染的方法。
• Phenylthiazoles with tert-Butyl side chain: Metabolically stable with anti-biofilm activity
  作者：Ahmed Kotb、Nader S. Abutaleb、Mohamed A. Seleem、Mohamed Hagras、Haroon Mohammad、Ashraf Bayoumi、Adel Ghiaty、Mohamed N. Seleem、Abdelrahman S. Mayhoub

  DOI：10.1016/j.ejmech.2018.03.044

  日期：2018.5

  A new series of phenylthiazoles with t-butyl lipophilic component was synthesized and their antibacterial activity against a panel of multidrug-resistant bacterial pathogens was evaluated. Five compounds demonstrated promising antibacterial activity against methicillin-resistant staphylococcal strains and several vancomycin-resistant staphylococcal and enterococcal species. Additionally, three derivatives 19, 23 and 26 exhibited rapid bactericidal activity, and remarkable ability to disrupt mature biofilm produced by MRSA USA300. More importantly, a resistant mutant to 19 couldn't be isolated after subjecting MRSA to sub-lethal doses for 14 days. Lastly, this new series of phenylthiazoles possesses an advantageous attribute over the first-generation compounds in their stability to hepatic metabolism, with a biological half-life of more than 9 h. (C) 2018 Elsevier Masson SAS. All rights reserved.
• [EN] PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS DE PYRIMIDINONE AMIDE EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016186888A1

  公开（公告）日：2016-11-24

  The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶酮酰胺化合物，可能作为治疗中枢神经系统和/或与磷酸二酯酶2（PDE2）相关的外周障碍的治疗剂。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病、阿尔茨海默病、认知障碍、焦虑、抑郁症、偏头痛或亨廷顿病、帕金森病、帕金森病痴呆（PDD）和与纹状体功能不足或基底神经节功能障碍相关的其他疾病。